Aethlon Medical

AEMD · NASDAQ

$5.31+$0.00 (+0.00%)TodayMarket closed · Oct 21, 4:08 AM ET

Prev close $5.31

AEMD analyst rating

This isn't available right now. Refresh to try again.

The case for and against

Updated Aug 7, 2025

Bull case

Aethlon Medical Inc. has received constructive feedback from clinical sites aimed at enhancing patient enrollment and reducing screening failures, potentially leading to quicker data collection and more timely top-line readouts from ongoing studies. The Hemopurifier demonstrates promising capabilities in improving outcomes not only in oncology and infectious diseases but also in organ transplantation, highlighting the device's versatile applications and addressing significant unmet medical needs. With $4.8 million in cash and recent cost-cutting measures, Aethlon is well-positioned to sustain its operations into the second half of 2025, which may further support shareholder confidence amid advancements in their clinical programs.

Bear case

Aethlon Medical Inc is facing significant financial challenges, as evidenced by its reported net loss of $1.8 million in F3Q25, reflecting ongoing operational deficits. The company is exposed to numerous risks, including the potential failure of clinical trials and an untested commercialization strategy, which could hinder its ability to bring the Hemopurifier to market effectively. Additionally, the possible expiration or invalidation of intellectual property rights and difficulties in securing further funding in adverse market conditions contribute to a concerning outlook for the company’s financial stability.

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.